{"disease":{"id":"acute-migraine","name":"Acute migraine","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:31:21.551Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":0,"pipeline_drug_count":1,"trial_count":0},"drugs":{"marketed":[{"drug_id":"rimegepant-75mg-every-other-day-dosing","indication_name":"Acute treatment of migraine attacks with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 75mg every other day dosing","generic_name":"rimegepant-75mg-every-other-day-dosing","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor","drug_class":"calcitonin gene-related peptide receptor antagonist","quality_score":64,"revenue":"798","mechanism":"Rimegepant targets the calcitonin gene-related peptide receptor to treat migraines."},{"drug_id":"eletriptan-hydrobromide","indication_name":"Acute treatment of migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ELETRIPTAN HYDROBROMIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"eletriptan","indication_name":"Acute treatment of migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Relpax","generic_name":"ELETRIPTAN","company_name":"Upjohn","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1D","drug_class":"Serotonin-1b and Serotonin-1d Receptor Agonist","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"naratriptan","indication_name":"Acute treatment of migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amerge","generic_name":"NARATRIPTAN","company_name":"GSK","drug_phase":"marketed","molecular_target":"5-HT 1B/1D receptors","drug_class":"Serotonin-1b and Serotonin-1d Receptor Agonist","quality_score":75,"revenue":null,"mechanism":"Naratriptan treats migraines by binding to 5-HT 1B/1D receptors, causing cranial vessel constriction and inhibiting neuropeptide release."},{"drug_id":"rizatriptan-benzoate","indication_name":"Acute treatment of migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"RIZATRIPTAN BENZOATE","company_name":"","drug_phase":"marketed","molecular_target":"5-HT 1B/1D receptors","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Rizatriptan treats migraines by binding to 5-HT 1B/1D receptors on blood vessels and nerves."},{"drug_id":"bhv-3500-zavegepant","indication_name":"Acute migraine treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BHV-3500 (zavegepant)","generic_name":"bhv-3500-zavegepant","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"CGRP receptor (calcitonin gene-related peptide receptor)","drug_class":"CGRP receptor antagonist","quality_score":30,"revenue":null,"mechanism":"Zavegepant is a CGRP receptor antagonist that blocks neuropeptide signaling to reduce migraine pain and associated symptoms."},{"drug_id":"bhv-3500-zavegepant","indication_name":"Acute migraine treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BHV-3500 (zavegepant)","generic_name":"bhv-3500-zavegepant","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"CGRP receptor (calcitonin gene-related peptide receptor)","drug_class":"CGRP receptor antagonist","quality_score":30,"revenue":null,"mechanism":"Zavegepant is a CGRP receptor antagonist that blocks neuropeptide signaling to reduce migraine pain and associated symptoms."},{"drug_id":"rimegepant-for-acute-migraine-treatment","indication_name":"Acute treatment of migraine with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant for acute migraine treatment","generic_name":"rimegepant-for-acute-migraine-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor","drug_class":"calcitonin gene-related peptide receptor antagonist","quality_score":54,"revenue":null,"mechanism":"Rimegepant targets the calcitonin gene-related peptide receptor to treat acute migraine."},{"drug_id":"rimegepant-75mg-orally-disintegrating-tablets-odt","indication_name":"Acute treatment of migraine attacks with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 75mg Orally Disintegrating Tablets (ODT)","generic_name":"rimegepant-75mg-orally-disintegrating-tablets-odt","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor","drug_class":"calcitonin gene-related peptide receptor antagonist","quality_score":51,"revenue":null,"mechanism":"Rimegepant is a calcitonin gene-related peptide receptor antagonist."},{"drug_id":"rimegepant-75mg-daily-dosing","indication_name":"Acute treatment of migraine attacks with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 75mg daily dosing","generic_name":"rimegepant-75mg-daily-dosing","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor","drug_class":"calcitonin gene-related peptide receptor antagonist","quality_score":53,"revenue":null,"mechanism":"Rimegepant is a calcitonin gene-related peptide receptor antagonist that inhibits the release of pro-inflammatory peptides."},{"drug_id":"rimegepant-bhv3000","indication_name":"Acute treatment of migraine with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant/BHV3000","generic_name":"rimegepant-bhv3000","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor (CGRPR)","drug_class":"pharmacological class not specified","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"rimegepant-25-mg","indication_name":"Acute treatment of migraine with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 25 MG","generic_name":"rimegepant-25-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor","drug_class":"calcitonin gene-related peptide receptor antagonist","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"triptans","indication_name":"Acute treatment of migraine attacks with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Triptans","generic_name":"triptans","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Serotonin 5-HT1B/1D receptors","drug_class":"Selective serotonin receptor agonists","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"rimegepant-75-mg-odt","indication_name":"Acute treatment of migraine with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"rimegepant 75 mg ODT","generic_name":"rimegepant-75-mg-odt","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CGRP receptors","drug_class":"CGRP receptor antagonist","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"zolmitriptan","indication_name":"Acute treatment of migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zomig","generic_name":"ZOLMITRIPTAN","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1D","drug_class":"Serotonin-1b and Serotonin-1d Receptor Agonist [EPC]","quality_score":75,"revenue":null,"mechanism":"Zolmitriptan works by binding to serotonin receptors in the brain to constrict blood vessels and block pain pathways."}],"pipeline":[{"drug_id":"bhv-3500-zavegepant","indication_name":"Acute migraine","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BHV-3500 (zavegepant)","generic_name":"bhv-3500-zavegepant","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"CGRP receptor (calcitonin gene-related peptide receptor)","drug_class":"CGRP receptor antagonist","quality_score":30,"revenue":null,"mechanism":"Zavegepant is a CGRP receptor antagonist that blocks neuropeptide signaling to reduce migraine pain and associated symptoms."},{"drug_id":"rimegepant-75-mg","indication_name":"Acute treatment of migraine with or without aura","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 75 MG","generic_name":"rimegepant-75-mg","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"Calcitonin gene-related peptide (CGRP) receptor","drug_class":"CGRP receptor antagonist (gepant)","quality_score":25,"revenue":null,"mechanism":"Rimegepant selectively antagonizes the calcitonin gene-related peptide (CGRP) receptor to block migraine pain signaling."},{"drug_id":"rimegepant-75-mg","indication_name":"Acute treatment of migraine in pediatric subjects","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 75 MG","generic_name":"rimegepant-75-mg","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"Calcitonin gene-related peptide (CGRP) receptor","drug_class":"CGRP receptor antagonist (gepant)","quality_score":25,"revenue":null,"mechanism":"Rimegepant selectively antagonizes the calcitonin gene-related peptide (CGRP) receptor to block migraine pain signaling."}],"offLabel":[],"totalMarketed":15,"totalPipeline":3},"trials":{"data":[{"nct_id":"NCT06976723","title":"Nerivio Efficacy by Time of Treatment Onset","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":55261,"lead_sponsor_name":"Theranica","has_results":false},{"nct_id":"NCT04806620","title":"Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Brain Inflammation Collaborative","has_results":false},{"nct_id":"NCT04574362","title":"Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1648,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04031469","title":"A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease","phase":"","overall_status":"SUSPENDED","enrollment_count":1000,"lead_sponsor_name":"ProgenaBiome","has_results":false},{"nct_id":"NCT04408794","title":"Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":974,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05754190","title":"Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"Brown University","has_results":false},{"nct_id":"NCT01004263","title":"A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long Term Treatment of Acute Migraine in Children and Adolescents (MK-0462-086 AM3)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":674,"lead_sponsor_name":"Organon and Co","has_results":true},{"nct_id":"NCT04743141","title":"Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT07336420","title":"Treatment Patterns Among US Veterans Using Remote Electrical Neuromodulation (REN) for Migraine Treatment","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":466,"lead_sponsor_name":"Theranica","has_results":false},{"nct_id":"NCT06848075","title":"A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":431,"lead_sponsor_name":"Kallyope Inc.","has_results":false},{"nct_id":"NCT04218162","title":"Lasmiditan Compared to Placebo in the Acute Treatment of Migraine in Korean","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":294,"lead_sponsor_name":"IlDong Pharmaceutical Co Ltd","has_results":false},{"nct_id":"NCT06738056","title":"Nerivio Long-term Usage in Patients With Migraine","phase":"","overall_status":"COMPLETED","enrollment_count":244,"lead_sponsor_name":"Theranica","has_results":false},{"nct_id":"NCT05371652","title":"A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":241,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03631550","title":"The RIME Study - Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation for Treatment of Migraine","phase":"NA","overall_status":"COMPLETED","enrollment_count":187,"lead_sponsor_name":"Neurolief Ltd.","has_results":true},{"nct_id":"NCT05641363","title":"Comparison of Ketorolac at Three Doses in Children With Acute Pain","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":171,"lead_sponsor_name":"Hamilton Health Sciences Corporation","has_results":false},{"nct_id":"NCT07015125","title":"Evaluation of a Wearable Device for Acute Treatment of Migraines","phase":"NA","overall_status":"COMPLETED","enrollment_count":160,"lead_sponsor_name":"Hinge Health, Inc","has_results":false},{"nct_id":"NCT03338920","title":"Study to Assess the Safety and Efficacy of ONZETRA® Xsail® for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":159,"lead_sponsor_name":"Currax Pharmaceuticals","has_results":true},{"nct_id":"NCT07116499","title":"A Study of K-645 in the Treatment of Multiple Migraine Attacks","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":134,"lead_sponsor_name":"Kallyope Inc.","has_results":false},{"nct_id":"NCT03076515","title":"Migraine Treatment With Nerivio Migra Neurostimulation Device","phase":"NA","overall_status":"TERMINATED","enrollment_count":120,"lead_sponsor_name":"Theranica","has_results":true},{"nct_id":"NCT00894556","title":"A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":109,"lead_sponsor_name":"Organon and Co","has_results":true},{"nct_id":"NCT04089761","title":"Safety and Efficacy of Nerivio™ for the Acute Treatment of Migraine in Adolescents","phase":"NA","overall_status":"TERMINATED","enrollment_count":60,"lead_sponsor_name":"Theranica","has_results":true},{"nct_id":"NCT05983354","title":"Oral Medications for the Management of Acute Migraine Headache in the Emergency Department","phase":"NA","overall_status":"UNKNOWN","enrollment_count":55,"lead_sponsor_name":"Health Sciences North Research Institute","has_results":false},{"nct_id":"NCT04153409","title":"A Proof of Concept Study of the Efficacy and Safety of Oral LAT8881 in Acute Migraine","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Lateral Pharma Pty Ltd","has_results":true},{"nct_id":"NCT06995729","title":"A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":16,"lead_sponsor_name":"Pfizer","has_results":false}],"total":24},"guidelines":[],"source":"Drug Landscape verified database"}